Biotech lands $35m to combat cognitive decline with ‘longevity protein’

Jocasta targets clinical trials of klotho-based therapy in 2026, building on technology licensed from Unity Bio. While the recent demise of Unity Biotechnology came as a blow to the longevity field, its impact on the field will continue to be felt for many years to come, including through the work b…